Improve Medical Instruments Co., Ltd. (SHE:300030)
China · Delayed Price · Currency is CNY 8.32
+0.12 (1.46%)
Feb 13, 2026, 3:04 PM CST
SHE:300030 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 503.1 | 575.33 | 635.17 | 705.16 | 793.98 | 904.99 |
Other Revenue | 5.99 | 5.99 | 9.45 | 5.61 | 5.86 | 14.24 |
| 509.09 | 581.33 | 644.62 | 710.77 | 799.83 | 919.23 | |
Revenue Growth (YoY) | -14.25% | -9.82% | -9.31% | -11.14% | -12.99% | 59.85% |
Cost of Revenue | 317.39 | 368.51 | 414.5 | 474.56 | 490.54 | 498.86 |
Gross Profit | 191.7 | 212.81 | 230.12 | 236.21 | 309.29 | 420.37 |
Selling, General & Admin | 159.29 | 180.76 | 225.16 | 239.4 | 219.24 | 216.59 |
Research & Development | 26.47 | 31.9 | 37.52 | 43.67 | 42.33 | 46.56 |
Other Operating Expenses | 7.22 | 6.11 | 4.03 | 4.96 | 7.08 | 7.57 |
Operating Expenses | 211.97 | 242.72 | 263.62 | 297.12 | 276.4 | 274.86 |
Operating Income | -20.27 | -29.91 | -33.5 | -60.91 | 32.89 | 145.51 |
Interest Expense | -5.82 | -11.09 | -16.56 | -19.7 | -25.44 | -24.69 |
Interest & Investment Income | 19.92 | 1.82 | 8.55 | 2.45 | 20.76 | 83.22 |
Currency Exchange Gain (Loss) | 1.2 | 1.2 | -0.84 | 2.38 | -1.56 | -4.61 |
Other Non Operating Income (Expenses) | 0.99 | 0.67 | -3.51 | -2.11 | -6.53 | -42.66 |
EBT Excluding Unusual Items | -3.98 | -37.31 | -45.87 | -77.89 | 20.11 | 156.77 |
Impairment of Goodwill | -11.87 | -11.87 | -2.93 | -53.62 | - | - |
Gain (Loss) on Sale of Investments | -23.56 | -63.56 | 1.21 | -53.1 | 6.41 | 7.68 |
Gain (Loss) on Sale of Assets | -0.47 | 0.9 | 6.45 | 0.44 | 0.02 | -0.17 |
Asset Writedown | -15.57 | -11.47 | -6.05 | -36.45 | -1.39 | -10.41 |
Legal Settlements | - | - | -2.44 | -0.56 | - | - |
Other Unusual Items | 4.37 | 2.96 | 6.57 | 6.88 | -1.3 | 11.22 |
Pretax Income | -51.08 | -120.35 | -43.06 | -214.3 | 23.84 | 165.09 |
Income Tax Expense | 0.74 | -0.45 | 17.16 | -21.01 | 4.07 | 1.77 |
Earnings From Continuing Operations | -51.82 | -119.9 | -60.22 | -193.29 | 19.77 | 163.32 |
Minority Interest in Earnings | 0.48 | 2 | -2.98 | -5.01 | -1.2 | -0.81 |
Net Income | -51.34 | -117.9 | -63.2 | -198.3 | 18.57 | 162.52 |
Net Income to Common | -51.34 | -117.9 | -63.2 | -198.3 | 18.57 | 162.52 |
Net Income Growth | - | - | - | - | -88.57% | 524.48% |
Shares Outstanding (Basic) | 308 | 310 | 316 | 310 | 309 | 307 |
Shares Outstanding (Diluted) | 308 | 310 | 316 | 310 | 309 | 307 |
Shares Change (YoY) | 0.98% | -1.82% | 1.99% | 0.12% | 0.93% | -5.74% |
EPS (Basic) | -0.17 | -0.38 | -0.20 | -0.64 | 0.06 | 0.53 |
EPS (Diluted) | -0.17 | -0.38 | -0.20 | -0.64 | 0.06 | 0.53 |
EPS Growth | - | - | - | - | -88.68% | 562.50% |
Free Cash Flow | 90.48 | 30.55 | 36.2 | -15.56 | 100.69 | 84.46 |
Free Cash Flow Per Share | 0.29 | 0.10 | 0.12 | -0.05 | 0.33 | 0.28 |
Dividend Per Share | - | - | - | - | 0.040 | 0.032 |
Dividend Growth | - | - | - | - | 25.00% | - |
Gross Margin | 37.66% | 36.61% | 35.70% | 33.23% | 38.67% | 45.73% |
Operating Margin | -3.98% | -5.15% | -5.20% | -8.57% | 4.11% | 15.83% |
Profit Margin | -10.08% | -20.28% | -9.80% | -27.90% | 2.32% | 17.68% |
Free Cash Flow Margin | 17.77% | 5.26% | 5.62% | -2.19% | 12.59% | 9.19% |
EBITDA | 14.18 | 4.96 | 1.93 | -21.65 | 73.54 | 182.99 |
EBITDA Margin | 2.79% | 0.85% | 0.30% | -3.05% | 9.20% | 19.91% |
D&A For EBITDA | 34.45 | 34.87 | 35.43 | 39.26 | 40.65 | 37.48 |
EBIT | -20.27 | -29.91 | -33.5 | -60.91 | 32.89 | 145.51 |
EBIT Margin | -3.98% | -5.15% | -5.20% | -8.57% | 4.11% | 15.83% |
Effective Tax Rate | - | - | - | - | 17.08% | 1.07% |
Revenue as Reported | 509.09 | 581.33 | 644.62 | 710.77 | 799.83 | 919.23 |
Advertising Expenses | - | 17.77 | 24.75 | 25.27 | 30.74 | 32.56 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.